Skip to main content

Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
new molecular entities (NMEs)
Description

This analysis aimed to characterize users of 51 new molecular entities (NMEs) that were approved by the FDA in 2021 in the TriNetX Live™ platform. This query ran on January 19, 2024 and the analysis contains two reports: 

  • Report 1: This report contains data from 43 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with No Shift from January 1, 2021 to the most recently available data, January 19, 2024.
  • Report 2: This report contains contains data from 50 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from December 18, 2020 to the most recently available data, January 19, 2024.
Deliverables (2)
Sentinel Modular Report: Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis, Report 1 Sentinel Modular Report: Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
December 18, 2020 - January 19,2024; January 1, 2021- January 19, 2024
Analysis Type
TriNetX Analysis
Population / Cohort
All Individuals
Data Sources
TriNetX USA Network
Related Links
Sentinel Drug Study: New Molecular Entities (NMEs) & Utilization Characterization